NovaBay Pharmaceuticals Company Profile (NYSE:NBY)

About NovaBay Pharmaceuticals (NYSE:NBY)

NovaBay Pharmaceuticals logoNovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NYSE:NBY
  • CUSIP: N/A
  • Web: N/A
  • Market Cap: $42.04 million
  • Outstanding Shares: 15,288,000
Average Prices:
  • 50 Day Moving Avg: $3.27
  • 200 Day Moving Avg: $3.74
  • 52 Week Range: $2.12 - $5.29
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $11.9 million
  • Price / Sales: 3.53
  • Book Value: $0.47 per share
  • Price / Book: 5.85
  • EBIDTA: ($10,710,000.00)
  • Average Volume: 16,573 shs.
  • Short Ratio: 7.22

Frequently Asked Questions for NovaBay Pharmaceuticals (NYSE:NBY)

What is NovaBay Pharmaceuticals' stock symbol?

NovaBay Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "NBY."

How were NovaBay Pharmaceuticals' earnings last quarter?

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) released its earnings results on Thursday, August, 11th. The company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.06. The company earned $2.70 million during the quarter, compared to analysts' expectations of $1.76 million. View NovaBay Pharmaceuticals' Earnings History.

Where is NovaBay Pharmaceuticals' stock going? Where will NovaBay Pharmaceuticals' stock price be in 2017?

4 equities research analysts have issued 12-month target prices for NovaBay Pharmaceuticals' shares. Their forecasts range from $6.00 to $10.00. On average, they expect NovaBay Pharmaceuticals' share price to reach $7.33 in the next twelve months. View Analyst Ratings for NovaBay Pharmaceuticals.

What are analysts saying about NovaBay Pharmaceuticals stock?

Here are some recent quotes from research analysts about NovaBay Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of antimicrobial compounds, which it has named Aganocide compounds, which are based upon small molecules that are generated by white blood cells that defend the body against invading pathogens. NovaBay believes that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of bacterial and viral infections, including Methicillin-Resistant Staphylococcus aureus. " (5/17/2017)
  • 2. Maxim Group analysts commented, "NovaBay reported 4Q16 revenue of 4M, inline with preannouncement back in January. Operating expenses were $6.1M up from the prior quarter's $5.5M. This translated into a net loss of $1.6M or $(0.11) per share. Novabay ended the quarter with $9.5M in cash or about $7M (est.) in cash today... We have adjusted our model to reflect the revenue guidance. We conclude that without a revenue breakout, (driven by additional capital), our model suggests a target valuation in the current range. As such, we maintain our Hold rating." (3/24/2017)

Who are some of NovaBay Pharmaceuticals' key competitors?

Who owns NovaBay Pharmaceuticals stock?

NovaBay Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of America Corp DE (0.51%). View Institutional Ownership Trends for NovaBay Pharmaceuticals.

How do I buy NovaBay Pharmaceuticals stock?

Shares of NovaBay Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NovaBay Pharmaceuticals stock cost?

One share of NovaBay Pharmaceuticals stock can currently be purchased for approximately $2.75.

Analyst Ratings

Consensus Ratings for NovaBay Pharmaceuticals (NYSE:NBY) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $7.33 (166.67% upside)

Analysts' Ratings History for NovaBay Pharmaceuticals (NYSE:NBY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/13/2017Maxim GroupReiterated RatingHoldLowView Rating Details
3/26/2017HC WainwrightSet Price TargetBuy$6.00MediumView Rating Details
3/27/2017LaidlawInitiated CoverageBuy -> Buy$10.00MediumView Rating Details
2/6/2017Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 5/26/2015 forward)


Earnings History for NovaBay Pharmaceuticals (NYSE:NBY)
Earnings by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)
Earnings History by Quarter for NovaBay Pharmaceuticals (NYSE:NBY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016Q316($0.16)($0.34)$3.02 million$3.40 millionViewN/AView Earnings Details
8/11/2016Q216($0.30)($0.36)$1.76 million$2.70 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NovaBay Pharmaceuticals (NYSE:NBY)
Current Year EPS Consensus Estimate: $-0.54 EPS
Next Year EPS Consensus Estimate: $-0.10 EPS


Dividend History for NovaBay Pharmaceuticals (NYSE:NBY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NovaBay Pharmaceuticals (NYSE:NBY)
No insider trades for this company have been tracked by


Headline Trends for NovaBay Pharmaceuticals (NYSE:NBY)
Latest Headlines for NovaBay Pharmaceuticals (NYSE:NBY)
DateHeadline logoTetraphase Pharmaceuticals, Inc. (TTPH) - May 19 at 11:31 AM logoNovaBay Pharmaceuticals, Inc. (NBY) Upgraded by Zacks Investment Research to "Hold" - May 18 at 11:34 PM logoNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q1 2017 Results - Earnings Call Transcript - May 12 at 7:25 PM logoNovaBay Pharmaceuticals to Hold 2017 First Quarter Conference Call on May 11, 2017 - May 4 at 11:27 AM logoZacks: NovaBay Pharmaceuticals, Inc. (NBY) Given $6.00 Average Price Target by Analysts - May 4 at 9:17 AM logoNovaBay Pharmaceuticals (NBY) Earns Media Sentiment Score of 0.44 - May 3 at 12:20 AM logoAvenova from NovaBay Pharmaceuticals is Effective for Managing Dry Eye before Refractive and Cataract Eye Surgery - May 2 at 6:59 PM logoNovaBay Pharmaceuticals (NBY) Receives Daily Media Sentiment Score of -0.39 - April 29 at 7:39 AM logoNovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable News Coverage, Analysis Shows - April 26 at 6:14 PM logoNovaBay Pharmaceuticals (NBY) Receiving Positive News Coverage, Study Finds - April 21 at 7:17 PM logo NovaBay Pharmaceuticals, Inc. (NBY) Given $6.00 Consensus Target Price by Analysts - April 17 at 6:37 PM logoNovaBay Pharmaceuticals (NBY) Getting Somewhat Favorable Media Coverage, Report Finds - April 17 at 3:58 PM logoNovaBay Pharmaceuticals, Inc. (NBY) Downgraded to "Sell" at Zacks Investment Research - April 15 at 8:42 AM logoNovaBay Pharmaceuticals' (NBY) Hold Rating Reiterated at Maxim Group - April 1 at 11:31 PM logoNovaBay Pharmaceuticals, Inc. (NBY) Coverage Initiated by Analysts at Laidlaw - March 31 at 11:50 AM logoNovaBay Pharmaceuticals, Inc. (NBY) Receives "Hold" Rating from Maxim Group - March 30 at 9:10 AM logoAnalysts Anticipate NovaBay Pharmaceuticals, Inc. (NBY) to Announce ($0.14) Earnings Per Share - March 29 at 12:20 PM logoAvenova from NovaBay Pharmaceuticals Effective for Painful Eye Condition - March 28 at 10:11 AM logoNovaBay Pharmaceuticals, Inc. (NBY) Given a $6.00 Price Target at HC Wainwright - March 27 at 2:49 PM logoU.S. Stocks Post Worst Week Since Election as Health Bill Fails - March 24 at 6:43 PM logoNovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference - March 7 at 10:13 AM logoNovaBay sees 171% jump in 2016 revenues; shares ahead 8% - January 9 at 7:28 PM logoNovaBay Pharma (NBY) Notes Positive OCLI Publication on Avenova - November 29 at 2:40 PM logoNovaBay Pharma (NBY) Misses Q3 EPS by 18c - November 11 at 6:05 PM logoNovaBay Pharmaceuticals' (NBY) CEO Mark Sieczkarek on Q3 2016 Results - Earnings Call Transcript - November 11 at 6:05 PM logoNovaBay regains compliance with NYSE continued listing requirements - October 31 at 1:07 PM logoNovaBay Pharmaceuticals Complies With NYSE Listing Requirements - October 31 at 1:07 PM logoNovaBay pulls in $7M from exercise of warrants - October 3 at 10:55 AM logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of NovaBay Pharmaceuticals, Inc. - NBY - September 23 at 3:30 PM logo15 Stocks Moving In Monday's Pre-Market Session - September 19 at 8:39 AM logoNovaBay misses by $0.56, misses on revenue - Seeking Alpha - May 13 at 7:21 AM logoNovaBay Pharmaceuticals to Hold First Quarter 2016 Conference Call on May 12 - May 5 at 7:00 AM logoNovaBay Says Its Avenova Cuts Bacteria On Ocular Skin Surface By Over 90% - Benzinga - May 4 at 6:17 AM logoNovaBay Pharma (NBY) Enters $12M Securities Purchase Agreement - - April 6 at 12:56 PM logoNovaBay Pharmaceuticals to Present at 28th Annual ROTH Conference - Business Wire (press release) - March 8 at 1:08 PM logoNovaBay Pharma (NBY) Announces $2.83M Private Placement - - February 24 at 7:47 PM logo4:50 pm NovaBay Pharma confirms $2.83 mln private placement - February 24 at 4:50 PM logoNovaBay Pharmaceuticals Announces $2.83 Million Private Placement - February 24 at 4:48 PM



NovaBay Pharmaceuticals (NBY) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by Staff